N- methyl- N- (1- methyl- 4- pyrrolidino- 2- butynyl)acetamide (BM 5)

RN given refers to parent cpd without isomeric designation

Also Known As:

BM 5; BM-5; N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide oxalate (1:1); N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide, (+-)-isomer; N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide, (R)-isomer; N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide, (S)-isomer

Networked: 10 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide: 10

Experts

1.	Arnett, Andrea: 1 article (01/2022)
2.	Bazan, Jose: 1 article (01/2022)
3.	Beyer, Sasha: 1 article (01/2022)
4.	Blakaj, Dukagjin: 1 article (01/2022)
5.	Chakravarti, Arnab: 1 article (01/2022)
6.	Elder, James B: 1 article (01/2022)
7.	Fabian, Denise: 1 article (01/2022)
8.	Giglio, Pierre: 1 article (01/2022)
9.	Grecula, John: 1 article (01/2022)
10.	Haglund, Karl: 1 article (01/2022)

Related Diseases

1.	Tremor (Tremors) 01/01/1987 - "The tremor response to BM-5 was bell-shaped, the peak dose being around 2 mg/kg. In contrast, the salivary response increased with increasing doses of BM-5. " 01/01/1987 - "In vivo studies in mice and rats indicated that this compound is a partial muscarinic agonist with large regional differences in its efficacy: BM-5 produced low tremor in doses which evoke full salivary response. " 01/01/1987 - "Chronic treatment of mice with BM-5 (0.2-2 mg/kg) for 14 days also showed that BM-5 at higher doses, behaved as an antagonist, since it caused supersensitivity to oxotremorine on the tremor response. " 01/01/1987 - "The maximal tremor response to BM-5 was much smaller than that produced by oxotremorine, while the maximal salivary response to BM-5 was greater than that evoked by oxotremorine. " 08/01/1987 - "Compounds such as AKS 19 and BM 5 having low intrinsic efficacy (partial agonists) differentiated between centrally mediated muscarinic effects as they, like oxotremorine, were potent in producing analgesia and hypothermia but did not produce tremor. "
2.	Infections 01/01/1999 - "In a previous report, we showed that Anticarsia gemmatalis nucleopolyhedrovirus (AgMNPV) infections of Choristoneura fumiferana IPRI-CF-124T and Bombyx mori BM-5 cell lines are abortive, whereas A. " 01/01/1997 - "Infections of Bombyx mori BM-5 cell lines were abortive, and cells had apoptosis-like morphology. "
3.	Melanoma (Melanoma, Malignant) 01/01/2022 - "10 patients were enrolled (median age-59 [47-64], BM-5 [1-10], 50% melanoma). "
4.	Lymphoma (Lymphomas) 07/01/1993 - "Eighteen patients with malignant lymphoma, 10 non-Hodgkin's and 8 Hodgkin's, were treated with high-dose CVB (cyclophosphamide 4 x 1.5 g/m2, etoposide 4 x 250-400 mg/m2, carmustine 4 x 150-200 mg/m2), followed by autologous peripheral blood stem cells (PBSC, 13 patients) or bone marrow (BM, 5 patients) transplantation. "
5.	Hypothermia 08/01/1987 - "Compounds such as AKS 19 and BM 5 having low intrinsic efficacy (partial agonists) differentiated between centrally mediated muscarinic effects as they, like oxotremorine, were potent in producing analgesia and hypothermia but did not produce tremor. "

Related Drugs and Biologics

1.	Muscarinic Agonists
2.	Oxotremorine
3.	Cholinergic Agents (Cholinergics)
4.	Ointments (Pastes)
5.	Indomethacin (Indometacin)
6.	Etoposide (VP 16)
7.	Cyclophosphamide (Cytoxan)
8.	Carmustine (FIVB)
9.	Bufexamac (Jomax)
10.	Betamethasone Valerate (Betamethasone 17 Valerate)

Related Therapies and Procedures

1.	Transplantation
2.	Analgesia